These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 22894970)
21. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy]. Van den Eynde B Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005 [TBL] [Abstract][Full Text] [Related]
22. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. Kim CG; Sang YB; Lee JH; Chon HJ Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360800 [TBL] [Abstract][Full Text] [Related]
24. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011 [TBL] [Abstract][Full Text] [Related]
25. A new era of cancer immunotherapy: converting theory to performance. Rosenberg SA CA Cancer J Clin; 1999; 49(2):70-3, 65. PubMed ID: 11198888 [TBL] [Abstract][Full Text] [Related]
26. Regulatory considerations for clinical development of cancer vaccines. Heelan BT Hum Vaccin Immunother; 2014; 10(11):3409-14. PubMed ID: 25625933 [TBL] [Abstract][Full Text] [Related]
28. [Epitope peptide vaccine with oncoantigen for cancer and its biomarker]. Hazama S; Maeda K; Oka M Nihon Rinsho; 2012 Dec; 70(12):2189-93. PubMed ID: 23259395 [TBL] [Abstract][Full Text] [Related]
29. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic cancer vaccines: at midway between immunology and pharmacology. Lage A; Perez R; Fernandez LE Curr Cancer Drug Targets; 2005 Dec; 5(8):611-27. PubMed ID: 16375666 [TBL] [Abstract][Full Text] [Related]
31. Advances in strategies and methodologies in cancer immunotherapy. Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192 [TBL] [Abstract][Full Text] [Related]
32. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Seremet T; Brasseur F; Coulie PG Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282 [TBL] [Abstract][Full Text] [Related]
33. Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Aldous AR; Dong JZ Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369 [TBL] [Abstract][Full Text] [Related]
35. Cancer-testis antigens: An update on their roles in cancer immunotherapy. Taherian-Esfahani Z; Dashti S Hum Antibodies; 2019; 27(3):171-183. PubMed ID: 30909205 [TBL] [Abstract][Full Text] [Related]
37. Specificity in cancer immunotherapy. Schietinger A; Philip M; Schreiber H Semin Immunol; 2008 Oct; 20(5):276-85. PubMed ID: 18684640 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic cancer vaccines: From initial findings to prospects. Song Q; Zhang CD; Wu XH Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608 [TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy: will expanding knowledge lead to success in pediatric oncology? Fry TJ; Lankester AC Pediatr Clin North Am; 2008 Feb; 55(1):147-67, xi. PubMed ID: 18242319 [TBL] [Abstract][Full Text] [Related]